Integrating Isoniazid Preventive Therapy into the Fast-Track HIV Treatment Model in Urban Zambia: A Proof-of -Concept Pilot Project

Mpande Mukumbwa-Mwenechanya^{1*}, Muhau Mubiana¹, Paul Somwe¹, Khozya Zyambo², Maureen Simwenda³ Nancy Zongwe², Estella Kalunkumya¹, Linah Kampilimba Mwango⁴, Miriam Rabkin^{5,6}, Felton Mpesela⁷, Fred Chungu⁸, Felix Mwanza⁹, Peter Preko¹⁰, Carolyn Bolton-Moore^{1,11} Samuel Bosomprah ^{1,12} Anjali Sharma¹, Khunga Morton², Prisca Kasonde ¹³, Lloyd Mulenga², Patrick Lingu², Priscilla Lumano Mulenga²

- 1. Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia
- 2. Ministry of Health, Lusaka, Zambia
- 3. JSI USAID SAFE, Lusaka, Zambia
- 4. CIHEB Lusaka, Zambia
- 5. ICAP at Columbia University and Departments of Medicine & Epidemiology, New York, USA
- 6. Columbia University Mailman School of Public Health, New York, USA
- 7. Clinton Health Access, Lusaka, Zambia
- 8. Network of Zambian People Living with HIV, Lusaka Zambia
- 9. Treatment Advocacy and Literacy Campaign, Lusaka, Zambia
- 10. ICAP at Columbia University, Mbabane, Eswatini
- 11. University of Alabama at Birmingham, Birmingham, United States
- 12. Department of Biostatistics, School of Public Health, University of Ghana, Accra
- 13. ICAP at Columbia University, Lusaka, Zambia

Corresponding Author

Mpande Mukumbwa-Mwenechanya B.Pharm, MclinPharm, MSc Epidemiology Centre for Infectious Disease Research in Zambia

Plot 34620 Mass Media, Lusaka, Zambia 10101

+260966953010

E-mail addresses of authors:

MMM: Mpande.Mwenechanya@cidrz.org

MM: Muhau.Mubiana@cidrz.org

PS: Paul.Somwe@cidrz.org

KZ: <u>khozyazyambo@gmail.com</u>

MS:maureen_simwenda@jsh-z.com

- NZ: nancyzyongwe@gmail.com
- EK: Estella.Kalumkumya@cidrz.org
- LKM: <u>lkmwango@cihebzambia.org</u>
- MR: mr84@cumc.columbia.edu
- FM: fmpasela@clintonhealthaccess.org
- FC: fred.chungu@gmail.com
- FM: felimwa@yahoo.com
- PP:pp2332@cumc.columbia.edu
- CMB: <u>Carolyn.Bolton@cidrz.org</u>
- SB: <u>Samuel.Bosomprah@cidrz.org</u>
- AS: Anjali.Sharma@cidrz.org
- KM: mortonkhunga@yahoo.com
- PK: pk2587@cumc.columbia.edu
- LBM: https://www.ubmailto.com
- PL: lungupatrick99@gmail.com
- PLM: priscillalloyd2@icloud.com

Keywords: Integration, Isoniazid Preventive Therapy, HIV, Differentiated Service Delivery, Fast Track, Zambia

Word count: Abstract:349/350 Main text: 3492/3500

1 Abstract

| 2 | Introduction: Most people living with HIV (PLHIV) who are established on treatment in |
|----|---|
| 3 | Zambia receive multi-month prescribing and dispensing (MMSD) of antiretroviral therapy |
| 4 | (ART) and are enrolled in less-intensive differentiated service delivery (DSD) models, such as |
| 5 | Fast Track (FT), in which clients pick up ART every 3-6 months and make clinical visits to |
| 6 | health facilities every 6 months. In 2019, Zambia introduced Isoniazid Preventive Therapy (IPT) |
| 7 | with scheduled visits at 2 weeks and 1, 3, and 6 months. The asynchronous IPT and HIV |
| 8 | appointment schedules were inconvenient and not client centered. In response, we piloted |
| 9 | integrated MMSD/IPT in the FT HIV treatment model. |
| 10 | Methods: We implemented and evaluated a proof-of-concept pilot project at one purposively |
| 11 | selected high-volume facility in Lusaka, Zambia between July 2019 and May 2020. We |
| 12 | sensitized stakeholders, adapted training materials and standard operating procedures, and |
| 13 | screened adults in FT for TB as per national guidelines. Participants received structured TB/IPT |
| 14 | education, a 6-month supply of isoniazid and ART, an aligned 6th month IPT/MMSD clinic |
| 15 | appointment, and phone appointments at 2 weeks and months 1-5 following IPT initiation. We |
| 16 | used descriptive statistics to characterize IPT completion rates, phone appointment keeping, side |
| 17 | effect frequency and Fisher's exact test to determine if these varied by participant characteristics. |
| 18 | Notes from monthly meetings and discussions were used to synthesize key lessons learned. |
| 19 | Results: 1,167 clients were screened for eligibility and 818 (70.1%) were enrolled. Two thirds |
| 20 | (66%) were female, median age was 42 years, and 56.6% had been on ART for \geq 5 years. 738 |
| 21 | (90.2%) completed a 6-month course of IPT and 66 (8.1%) reported IPT-related side effects. 539 |
| 22 | clients (65.9%) attended all 7 telephone appointments. There were no significant differences in |
| 23 | these outcomes by age, sex, or time on ART. Lessons learnt include the value of promoting |

- 24 project ownership, client empowerment, securing supply chain, adapting existing processes, and
- 25 cultivating a collaborative structured learning environment.
- 26 Conclusions: Integrating multi-month dispensing and telephone follow up of IPT into the FT
- 27 HIV treatment model is a promising approach to scaling-up TB preventive treatment among
- 28 PLHIV, although limited by barriers to consistent phone access.

29 Word Count: 349 words

30 Introduction

Globally, tuberculosis (TB) is the direct cause of one-third of all human immunodeficiency virus

32 (HIV) related deaths and the leading cause of death among people living with HIV (PLHIV).¹

33 PLHIV account for approximately 10% of the 10 million annual new TB cases and on average,

have about 21-fold (CI: 16–27) higher risk of developing TB than HIV-negative persons.²⁻⁵

35 Zambia has one of the highest TB burdens in sub-Saharan Africa (SSA) and is ranked among the

top 30 TB control priority countries by the World Health Organization (WHO).¹ In 2021, the

estimated 59,000 new cases of TB in Zambia contributed to approximately 14,800 deaths among

38 Zambians, of which 9,100 (62%) occurred among PLHIV.^{2,3}

39 The WHO Global End TB strategy recommends provision of TB preventive treatment (TPT) for

40 PLHIV with the aim of eliminating TB by 2030. Whilst a priority and cost-effective, TPT

41 coverage and uptake has been low among PLHIV³ and current TPT coverage remains well under

42 WHO's 2025 coverage target (\geq 90%). ⁶⁻¹⁰ Commonly cited barriers for low uptake and coverage

- 43 include stock-outs, perceived fears of poor adherence and isoniazid (INH) resistance, inability to
- 44 prevent and monitor adverse events, a lack of local or national commitment, and perceived
- 45 difficulty of ruling out active TB. ¹¹⁻¹³

| 46 | In 2019, the Zambian Ministry of Health (MoH) adopted the WHO-recommended TPT strategy. ² |
|----------------------------------|---|
| 47 | The MoH TPT guidance provided for Isoniazid Preventive Therapy (IPT) dispensed at 2 weeks |
| 48 | and 1, 3 and 5 months for PLHIV established on treatment, defined as non-pregnant adults on |
| 49 | ART for greater than 6 months, with VL less than 1000 copies/mL, and without opportunistic |
| 50 | infections or active TB. This same population was eligible to enroll in Differentiated Service |
| 51 | Delivery (DSD) ¹⁴ for HIV treatment, enabled by multi-month (3-6 months) scripting and |
| 52 | dispensation (MMSD) of ART, shown to improve retention and viral suppression. ¹⁵ |
| | |
| 53 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual |
| 53 54 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual facility-based model in which clients visit health facilities every three months, alternating |
| 53 54 55 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual facility-based model in which clients visit health facilities every three months, alternating expedited medication pick up visits and clinical visits (Figure 1). ¹⁴ As of June 2021, 13% of |
| 53 54 55 56 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual facility-based model in which clients visit health facilities every three months, alternating expedited medication pick up visits and clinical visits (Figure 1). ¹⁴ As of June 2021, 13% of people on ART in Zambia had enrolled in FT. ¹⁵ Although integration of IPT into this model is an |
| 53 54 55 56 57 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual facility-based model in which clients visit health facilities every three months, alternating expedited medication pick up visits and clinical visits (Figure 1). ¹⁴ As of June 2021, 13% of people on ART in Zambia had enrolled in FT. ¹⁵ Although integration of IPT into this model is an important part of TPT scale up, the asynchronous appointment schedules for ART and IPT |
| 53 54 55 56 57 58 | One of the DSD models utilizing MMSD in Zambia is the Fast-Track (FT) model, an individual facility-based model in which clients visit health facilities every three months, alternating expedited medication pick up visits and clinical visits (Figure 1). ¹⁴ As of June 2021, 13% of people on ART in Zambia had enrolled in FT. ¹⁵ Although integration of IPT into this model is an important part of TPT scale up, the asynchronous appointment schedules for ART and IPT threatened DSD's "client centered" approach and retention in HIV-TB care. |

59 Figure 1: The Fast -Track HIV Treatment Mode

| Fast Track Eligibility Criteria | Fast Track Processes | | |
|--|---|--|--|
| Age > 18 years On ART > 12 months Viral load < 1,000 copies/mL No acute illness No complex comorbidities, opportunistic infections or active TB | Health facility visits every 3 months for accelerated pharmacy pick up and adherence counseling Health facility visits every 6 months for full clinical visits + pharmacy visit + adherence counseling | | |

60

Integrating multi-month dispensing of IPT into a rapidly growing DSD model for HIV care 61 offers a promising public health strategy to improve TPT uptake and prevention of TB among 62 PLHIV.¹⁶DSD models with longer refill intervals have demonstrated high rates of long-term 63 64 retention where 90% remained in care at four years compared to less than 70% in traditional facility-based HIV programs with monthly visits. 17-20 65

While case findings from SSA countries have shown that integration of MMSD TPT into DSD 66 models is feasible, the IPT refills were limited to a maximum of three months with minimal 67 evidence of adherence support and side effect monitoring at shorter intervals via phone. ^{14,21} 68 Furthermore, the use of mobile phones for continuous PLHIV monitoring and adherence support 69 and provision of 6MMSD TPT is silent in framework documents for programmatic 70 considerations of TPT implementation in DSD models.²¹ In response, we designed a proof-of-71 concept pilot project that integrated MMSD and IPT services in the FT DSD model by 72 synchronizing long refills of IPT (6 months MMSD) and visit schedules and utilized phone calls 73 74 to provide adherence support and side effect monitoring. The approach was piloted at a single health facility, given limited resources and the desire to start small and learn from experience. 75 Objectives included documenting the inputs, processes and enabling factors and challenges 76 involved in launching this new approach to TPT delivery, as well as client uptake, completion of 77 phone check-ins, and self-reported TPT completion rates and side effects. We did not attempt to 78 compare TPT outcomes vs. standard of care or to assess generalizability. 79

80 Methods

81 Study site

We purposively selected a high-volume HIV clinic serving more than 10,000 PLHIV active on ART (including 5,000 enrolled in FT) located within an urban primary level health center in Lusaka. We believed this site to be relatively common in our country (even if not typical) to quickly learn and generate valuable lessons that could contribute to the dialogue about integration of TPT into DSD models.

87 Study design and participants

- 88 The pilot was implemented in three phases: preparatory, enrollment, and intervention phase
- 89 (Figure 2). Inclusion criteria included age over 18 years, being established on ART as per
- 90 national guidelines, enrolled in FT, having access to a functioning phone, and willing to
- 91 participate. Exclusion criteria included recent or current IPT use, recent or current TB treatment,
- 92 current TB symptoms, and pregnancy. All clients that came to the facility during the one-month
- enrollment period (September 2019 October 2019) were eligible to enroll.

94 Figure 2: Project Implementation Timeline



95

96 We piloted the intervention, consisting of an adjusted IPT visit schedule; baseline education and

97 counselling; dispensing a 6 month-supply of both IPT and ART; phone check-ins at 2 weeks and

then monthly for 5 months; and a synchronized in-person follow-up visit for HIV and IPT care at

99 6 months (Figure 3).

100 Figure 3: Standard of Care vs. Intervention





102 Study procedures

Before protocol development, the pilot team carefully documented FT model processes and
reviewed the existing supply chain and infrastructure. This information was used to design the
intervention model (Figure 3) and to identify the appropriate facility staff to provide screening,
counselling, enrolment, IPT initiation and follow-up services.

107 Cognizant that a strong supply chain system that ensures availability of both INH and Pyridoxine

108 (Vitamin B6) was pivotal for project success,²² the project team engaged the NTP Pharmacist

and health facility Pharmacist to secure a constant supply of commodities. The project team

- 110 developed, and adapted training materials, standard operating procedures (SOPs) and data
- 111 collection tools and conducted stakeholder sensitization with Civil Society Organizations
- 112 (CSOs), healthcare workers (HCWs) and PLHIV to ensure initial and ongoing success of IPT
- incorporation into FT. Conducted in-person didactic training reorientated health centre staff to

standardized screening for IPT eligibility and management of patients on IPT including symptom
screening and counselling. In addition, community health workers (CHWs) were trained on
conducting structured phone follow-ups and provide referral for clinical consultations.

During the month-long enrolment phase (September 2019 - October 2019), HCWs routinely
screened adults in FT for pilot project eligibility. Eligible clients were invited to enroll in the
integrated IPT/ART model; participants then received structured health education messages on
the importance and benefits of IPT as well as identification, reporting and management of TB
symptoms/expected side effects. Enrollees received 6 months dispensation of INH (300mg),
pyridoxine (Vitamin B6) and their current ART regimen, and an appointment to return in 6
months.

During the intervention phase, CHW conducted phone follow-ups at 2 weeks, 4 weeks, and then 124 once monthly for 5 months. Structured checklist and script was utilized to assess IPT adherence 125 126 and any related side-effects and concerns/experiences (see Additional file, Section one). When participants were not available by phone after two failed attempts on two separate days, the 127 CHWs followed up with physical visits to their homes using the address provided by the clients 128 129 at enrollment. The study team shared these data at monthly meetings with all DSD staff at the facility to review progress, identify challenges, and to facilitate the use of quality improvement 130 131 methods to develop and test adjustments as needed. Notes from these meetings and discussions 132 were used to synthesize key lessons learned, we classified the success as enabling factors and 133 challenges as hindering factors of implementing this approach. The implementers, facility-based clinicians and community health workers assessed the tools and processes to be effective and 134 135 relatively efficient.

136 Data Collection and Management.

All participants were monitored for possible IPT related side effects, phone and in-person 137 appointment keeping, and IPT adherence and completion. Existing data collection systems and 138 tools such as the electronic medical records (EMR) and ART registers were adapted to capture 139 and record project data from month 3-9 of implementation (September 2019-April 2020) (Figure 140 141 2). In May 2020, pilot staff trained in research ethics and participant confidentiality extracted participant demographics, reported IPT-related side effects, appointment keeping and IPT 142 completion from the EMR. Data was checked for completeness, cleaned, and stored in a secured 143 and password-protected PostgreSQL database for analysis. We de-identified the data and only 144 included fields necessary for analysis. 145

146 Data Analysis

The primary outcome was self-reported IPT completion defined as completing the dispensed 6-147 month course of IPT. Secondary outcomes were reported side effects likely associated with IPT 148 (burning sensation in fingers and toes; itchy skin, yellow eyes, tongue and palms; joint pains; 149 nausea; vomiting; stomach pains and fever) and the percentage of scheduled phone appointments 150 completed. We used descriptive statistics including frequencies and proportions to describe 151 participant characteristics such as age, gender, time on ART and outcome variables. Fisher's 152 exact test was used to determine if participant demographics were statistically associated with 153 154 primary and secondary outcomes.

155 Ethical Consideration

The University of Zambia Biomedical Research Ethics Committee (UNZABREC) approved, and
the National Health Research Authority (NHRA) gave authority to conduct the pilot. Since this

- evaluation was implemented within routine ART program, signed informed consent was not a
- 159 requirement for participation.
- 160 Results

169

170

171

- 161 Participant Characteristics
- 162 A total of 1167 PLHIV were screened, of whom 818 (70.1%) were eligible and enrolled within
- the 30-day period. Of the 349 (29.9%) excluded, 172 (14.7%) had no phone; 122 (10.5%) were
- already on IPT; 30 (2.6%) had recently completed IPT/TB treatment; 13 (1.1%) had TB
- symptoms; 7 (0.6%) were pregnant; and 5 (0.4%) declined to participate in the pilot (Figure 4).
- 166 The 818 participants had median age of 42 years (IQR=35, 49), and 540 (66%) were females.
- 167 Over half (56.6%) of the participants were on ART for at least 5 years (Table 1).

168 Figure 4: Enrollment Flow Chart



| Characteristics | Number of participants (% of Total) | Number (%) | P- value | Number (%) Kept All | P- value | Number (%) Experienced | p- value |
|------------------------------|---|----------------|-------------|------------------------|-------------|------------------------------|-------------|
| | (70 01 10001) | treatment | | reponienci | | Side Effects | |
| Age (years): median (IQR) | 42, (35-49) | 42 (35-49) | | 42 (35-49) | | 44.5 (38-49) | |
| <30 | 89 (10.9%) | 77 (88.5%) | 0.22 | 60 (67.4%) | 0.91 | 2 (2.3%) | 0.2 |
| 30-39 | 270 (33%) | 242 (89.6%) | | 174 (64.4%) | | 18(6.7%) | |
| 40-49 | 286 (35%) | 263 (91.0%) | | 192 (67.1%) | | 30 (10.5%) | |
| 50+ | 173 (21.15%) | 156 (90.2%) | | 113(65.3%) | _ | 16 (9.25%% | |
| Sex | | | 0.73 | | 0.81 | | 0.5 |
| Female | 540 (66%) | 484 (89.6%) | | 354 (65.6%) | | 167(31.0%) | |
| Male | 278 (34%) | 254 (91.4%) | | 185 (66.6%) | | 86 (31.0%) | |
| ART Duration (years) | | | 0.20 | | 0.5 | | 0.5 |
| 1-2 | 61 (7.5%) | 52 (85.3%) | 1 | 37 (60.1%) | | 3(5%) | |
| 3-5 | 153 (18.7%) | 139 (90.9%) | | 106 (69.3%) | | 10(6.6%) | |
| 5+ years | 463 (56.6%) | 418 (90.3%) | | 299 (64.6%) | | 37 (8%) | |
| Missing | 141 (17.2%) | 129 (91.5%) | | 97 (68.8%) | | | 1 |
| Total | 818 (100%) | 738 | | 539 (65.9%) | | 66(8.1%) | |

172 Table 1: Baseline characteristics and outcomes of enrolled participants

173

174 IPT completion

- 175 Of the 818 enrolled participants, 738 (90.2%) reported completing the full 6-month course of
- 176 IPT; there were no significant differences in completion rate by age, sex, or duration on ART
- 177 (Table 1). Of the 80 (9.8%) of participants who did not complete the full course of IPT, 45
- 178 (5.5%) initiated IPT and then stopped due to medical advice as they experienced side effects, 21
- 179 (2.6%) were not evaluated, 10 (1.2%) were lost to follow-up and 3(0.4%) became pregnant

(Figure 4). One participant died in week 1 of the study but had not initiated IPT according to 180 their family. 181

Keeping scheduled appointments 182

- 183 Five hundred and thirty-nine (65.9%) participants kept all seven phone appointments; there were
- no significant differences in completion rate by age, sex, or duration on ART (Table 1). 184
- Appointment keeping was lower in the first three months of IPT initiation. (Figure 5). 185
- 186 Approximately 20% of participants did not keep their phone appointments at weeks 2, 4 and 8.
- Following two failed phone calls on two separate days a physical visit was then conducted, on 187
- average, 75% of these were reached physically and of these 95% reported adherence with IPT. 188



Figure 5: Completion of Phone Visits by Month 189

191

193 Reported Side Effects

- 194 Sixty-six participants (8.1%) reported side effects; there were no significant differences by age,
- sex, or duration on ART (Table 1). Reports of side effects were more frequent in the early weeks
- 196 of IPT (Figure 6). Whilst none of the side effects were classified as serious adverse event
- according to Zambia Medicines Regulatory Authority (ZAMRA) definition,²² forty-five (5.5%)
- 198 of participants were advised by their healthcare workers to discontinue IPT for fear of side
- 199 effects worsening during IPT administration. (Figure 4).



200 Figure 6: Reported Side Effects

201

202

203 Lessons learned: Successes

204 Effectively adapting existing processes and clinical tools

Adapting existing process and clinical tools ensured identification of the appropriate facility staff
 to provide screening, counselling, enrolment, IPT initiation and follow-up services. Additionally,

- it harmonised the tools (screening tools, clinical records and SOPs) thus minimized burden on
- facility staff and ensured that the intervention was not viewed as an additional responsibility.

209 Demand Creation and Client Empowerment

- 210 CHWs reported that the strategy of utilizing structured (1) educational messages messages and
- 211 (2) checklist and script empowered them to generate demand for the intervention, to allay
- 212 participants' concerns and consequently empowered participants to monitor and take charge of
- their health.

214 Cultivating a collaborative structured learning environment

- The monthly meetings at the facility cultivated an iterative and collaborative learning
- environment that promoted and provided a platform for initial and ongoing success of integrating
- 217 IPT into FT models.

218 **Promoting ownership**

The HCWs showed absolute involvement and support for this pilot project, which enabled theimplementation of this new approach.

221 Ensuring commodity security

- 222 Securing the supply chain system ensured constant availability of both INH and Pyridoxine
- 223 (Vitamin B6).
- 224 Lessons learned: Challenge
- 225 Phone usage

226 The intervention model included 7 phone check-ins over the 6-month intervention, meaning that access to phones was critical for pilot implementation and effectiveness. Although access to a 227 phone was an eligibility criterion, approximately 20% of participants did not keep their 228 appointments in week 2, months 1 and 2 as phones were either switched off or went unanswered 229 despite repeated attempts. For those not reached by phone, CHWs conducted in-person follow 230 231 ups to ascertain IPT adherence, about 75% were reached physically of whom 95% reported taking IPT as prescribed. During the in-person follow-ups, CHWs emphasized the importance of 232 the phone follow-ups this improved phone usage in subsequent months (Figure 5). 233

234 Discussion

This pilot represents one of the first examples of integrating long refills of TPT (6MMSD) into a 235 236 facility-based DSD model with utilization of phone calls at shorter intervals for continuous education, close monitoring and adherence support. We found that integration of TPT uptake 237 amongst participants was considerably higher than the national average, and self-reported TPT 238 239 completion rates were similar to those found nationwide. Our project builds on examples from case studies findings conducted in South Africa and the Democratic Republic of Congo that 240 indicated integration of TPT into DSD models could be successfully adopted as a TB screening 241 strategy and that longer refills of TPT were feasible.^{14,21} Additionally, findings of high IPT 242 243 completion rates and low reports of IPT side effects from this pilot are consistent with early findings from the implementation of IPT in DSD models in rural Uganda.²⁴ 244 In this pilot project we found that 90.2% of the participants who accepted this innovation 245

completed their IPT, similar to Zambia's reported national completion rate of (90%).²⁵ Although

247 design of this study did not include control or comparison groups, this high completion rate is

encouraging and may have been due to the combination of program efficiency and access to 248 ongoing phone-based counselling and support, which we believe is an innovative strategy of 249 facilitating social support. Studies by Grimsrud *et al.* and Nachenga *et al.* underscore the 250 significant contribution of social support in promoting IPT completion in community-based HIV 251 DSD models. ^{26,27} Further observations made by authors from South Africa and Uganda, where 252 253 higher ITP completion rates were reported in clients exposed to enhanced social support in both DSD community-based models and standard of care. ^{21,24, 28} Whilst our pilot integrated IPT in a 254 facility-based model, we believe that the continuous social support provided via phone promoted 255 256 treatment completion.

257 Furthermore, high completion rates seen in our pilot are concordant with evidence from a quality improvement collaborative in Uganda that showed 89% completion rates and two studies 258 conducted in Swaziland and Uganda that showed improvement of TPT completion in models 259 that integrated TB and HIV services.^{21,28,30} In Swaziland, IPT completion rates in facility based 260 (FB) models and community based (CB) models was reported at 89% and 91% respectively. 261 Both models utilized trained HCWs to provide support and counselling. ²⁸ Similarly, the 262 Ugandan cross-sectional study showed a higher completion rate in people in DSD models (72%) 263 than in routine care (53%). Results from this study suggested that the DSD models allowed for 264 stronger HCW- client relationship, education, communication and empowerment.²¹ 265

266 Uptake and coverage of IPT amongst PLHIV in Zambia ranges from 18% to 49% while in this

pilot 70.1% of all enrolled participants accepted the intervention.^{4,31} We hypothesize that the

person-centered and convenient model being piloted led to higher than usual 70.1% uptake rate.

269 DSD models that extended clinic visits have shown similar uptake success in HIV programs ³²⁻³⁴

thus, supporting clients preference for extended integrated visits.

Given the push to leverage DSD models to scale up TPT for PLHIV, it was important to evaluate 271 TPT in routine care, particularly in relation to side effects and treatment completion.³⁷ Collecting 272 and evaluating side effects data will capacitate the HCWs to reasonably inform patients 273 regarding the benefits versus risks of TPT. ³⁵HCWs have often conveyed fears of IPT medication 274 toxicity due to concomitant use with ART. ^{36,37} Our evaluation data showed that at 6 months of 275 IPT initiation only about 8.1% of the participants experienced side effects thus suggesting the 276 fears to be unfounded. These findings are corroborated by the 2019 Centre for Global Health 277 Division TPT myth and fact, which concluded that risk of adverse events in patients on TPT was 278 low, with <10% side effects recorded from various studies.³⁷ Additionally the national OI 279 collaborative in Uganda similarly reported that <10% of the study participants experienced INH 280 adverse events.³⁰ 281

This proof-of-concept pilot shows the importance of utilizing existing processes, establishing 282 283 HCWs project ownership, promoting client empowerment and fostering iterative and collaborative learning environment all of which were pivotal to the success. A 2019 debate of 284 lessons learnt during IPT implementation in Zambia closely linked programmatic issues such as 285 HCWs capacity to manage patients, limited demand for TPT services, drug stock outs and 286 patient IPT knowledge to the IPT completion and scale up.²² A week supply chain is a 287 significant hinderance to treatment completion and TPT scale up.^{26,27} In the prospective cohort 288 of improving IPT delivery in DSD models in Swaziland, erratic IPT supply was one of the 289 reasons for non-completion of TPT.²⁹ Therefore, securing the supply chain was useful for 290 291 implementation and maintenance of this pilot.

Strengths of this program evaluation include the innovative pilot design that does not only reducethe burden of patients frequenting the health facility, but moreover promotes MoH

recommendation of minimizing PLHIV side effects risks by ensuring exhaustive education of the 294 patients and close monitoring. ²Additionally provision of IPT long refills and utilization of phone 295 calls in between clinic visits is an intervention we believe may be leveraged to support uptake 296 and completion of other TPT regimens such as Isoniazid plus Rifampicin (3HP) and Isoniazid 297 plus Rifampicin (3HR) in Zambia.² Another strength of this pilot was the documentation of the 298 299 implementation process. Limitations include those typically associated with a single-site proofof-concept project of this kind: the absence of a control or comparison group other than historical 300 experience with IPT in Zambia, lack of TB infection outcomes reliance on self-report to assess 301 302 IPT completion, and the purposive selection of one urban health facility and the exclusion of PLHIV without phones, all of which limit the strength and generalizability of our results. The 303 description of lessons learnt draw on the experiences of the project team, and while we believe it 304 305 is important to share these experiences, we also recognize the subjective nature of the successes and challenges reported. Nonetheless, we are confident that the results of this pilot project will 306 contribute to the growing body of literature on the importance of integrating TPT and other 307 health services into DSD models for people with HIV.³⁸ 308

309 Conclusions

This pilot demonstrated that an integrated MMSD/IPT model involving synchronized IPT and HIV clinical visits, dispensing 6 months of IPT and ART, and delivering adherence counseling and follow up via phone was associated with excellent IPT uptake and completion rates. This promising public health strategy is worth further study and may improve coverage and completion of TPT amongst PLHIV, especially in countries that have taken DSD to scale and in which mobile phone penetration is high. Fostering project ownership, empowering clients, building health care worker capacity, collaboration with key stakeholders, mobilizing human

- resources and attending to supply chain security, were essential to successful pilot
- 318 implementation.
- 319 Word limit: 3492 words

322

323 Competing interests

324 None of the authors have conflicts to declare

325 Authors' contributions

- 326 MMM: Lead author, project design, data analysis and wrote the first draft
- 327 MM: Author, field coordination and data collection
- 328 PS: Conducted data analysis
- 329 KZ: Assisted with project conceptualization, project design and manuscript writing
- 330 MS: Assisted with and project design
- 331 NZ: Assisted with and project design
- 332 EK: Assisted with data collection and pilot implementation
- 333 LKM: Assisted with project conceptualization and design
- 334 MR: Assisted with manuscript development and writing
- 335 FM: Assisted with project conceptualization and design
- 336 FM: Assisted with project conceptualization and design
- 337 FC: Assisted with project conceptualization and design
- 338 FM: Assisted with project conceptualization ,design and implementation
- 339 PP: Assisted with project conceptualization and design
- 340 CBM: Advised with the implementation process
- 341 SB: Lead advisor on program evaluation and data analysis
- 342 AS: Assisted with manuscript writing
- 343 KM: Assisted with project conceptualization ,design and implementation

344 PK: Pilot conceptualization

- 345 LM: Technical guidance and pilot conceptualization
- 346 PL: Technical guidance and pilot conceptualization
- 347 PM: Assisted with project conceptualization ,design and writing

348 Acknowledgements

349 We are indebted to the Government of the Republic of Zambia, through the Ministry of Health,

350 for their valuable guidance and support during implementation . We would like to thank the DSD

351 Task Force and the TB National Program for leading the conceptualization and providing

352 meaningful guidance throughout. We are grateful to ICAP at Columbia University and the CQUIN

353 Learning Network for this great initiative that culminated into novel findings. Lastly, we thank

and salute the participants and health care workers for their efforts and contributions to the larger

355 vision of achieving epidemic control.

356 Copyright:

This is an open access article distributed under the terms of the <u>Creative Commons Attribution</u> <u>License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

360 Data Availability:

The Government of Zambia allows data sharing when applicable local conditions are satisfied. In this case, the data from the study will be made available to any interested researchers upon request. The CIDRZ Ethics and Compliance Committee is responsible for approving such request. To request data access, one must write to the Committee chair/Chief Scientific Officer, Dr. Roma Chilengi, (Roma.Chilengi@cidrz.org) or the Secretary to the Committee/Head of Research

| 366 | Operations, Ms. Hope Mwanyungwi (Hope.Mwanyungwi@cidrz.org) mentioning the intended |
|-----|--|
| 367 | use for the data. The Committee will then facilitate review and authorization to release the data as |
| 368 | requested. Data requests must include contact information, a research project title, and a |
| 369 | description of the intended use. |

370 Funding:

This work was supported in part, by the Bill & Melinda Gates Foundation [grant number OPP1152764]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might

arise from this submission.

375 **References**

- 1. WHO 2021 World Health Organization. The End TB Strategy. World Health
- 377 Organization, Geneva; 2021.<u>https://www.who.int/teams/global-tuberculosis-</u>
- 378 programme/the-end-tb-strategy
- 2. 2019, Ministry of Health National Tuberculosis Program Tuberculosis Preventive
 Treatment Guidelines
- World Health Organization. Global Tuberculosis Report 2018. World Health
 Organization, Geneva; 2018. https://apps.who.int/iris/handle/10665/274453
- 4. Gupta A, Lawn SD, et al. Tuberculosis incidence rates during 8 years of follow-up of an
 antiretroviral treatment cohort in South Africa: comparison with rates in the community.
- 385PLoS ONE 2012; 7: e34156.
- 5. Lawn SD, Harries AD, Williams BG, et al. Antiretroviral therapy and the control of
- 387 HIV-associated tuberculosis. Will ART do it? [Unresolved issues]. Int J Tuberc Lung
- 388 Dis 2011; 15: 571–81

| 389 | 6. | World Health Organization, 2015. A Guide to Monitoring and Evaluation for |
|-----|-----|--|
| 390 | | Collaborative TB/HIV Activities; 2015 Revision. Geneva, Switzerland: WHO; |
| 391 | | 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb- |
| 392 | | hiv/en/. |
| 393 | 7. | MacNeil A, Glaziou P, Sismanids C, Maloney S, Flyod K. Global epidemiology of |
| 394 | | tuberculosis and progress toward achiving global target_2017.MMWR Morb Mortal |
| 395 | | Wkly Rep 2019;68(11):263-6 |
| 396 | 8. | Pathmanathan I, Ahmedov , Pevzner E, Anyalechi G, Modi S, Kirking H et al .TB |
| 397 | | prevention therapy for people living with HIV :key considerations for scale up in |
| 398 | | resource limited settings. In J Tuberc Lung Dis 2018;22(6):596-605 |
| 399 | 9. | WHO. Available from https://www.who.int/tb/post2015_strategy/en/The End TB |
| 400 | | Strategy_Geneva, Switzerland: World Health Organization;2015 |
| 401 | 10. | World Health Organization. Global tuberculosis report, 2016. WHO/HTM/ TB/2016.13. |
| 402 | | Geneva, Switzerland: WHO, 2016. |
| 403 | 11. | Teklay G, Klinkenberg E, et al. Barriers in the implementation of isoniazid preventive |
| 404 | | therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and |
| 405 | | qualitative study. BMC Public Health; 2016 16: 840. |
| 406 | 12. | Moolphate S, Kaewkungwal J, et al. Barriers to and motivations for the implementation |
| 407 | | of a treatment programme for latent tuberculosis infection using isoniazid for people |
| 408 | | living with HIV, in upper northern Thailand. Glob J Health Sci; 2013 ,5: 60-70 |
| 409 | 13. | https://differentiatedservicedelivery.org/Portals/0/adam/Content/3qTmUzah5kWCdeEog |
| 410 | | diJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL%20(1).pdf |
| 411 | 14. | 2019, Zambia Differentiated Services Delivery National Framework. |

| 412 | 15. https://cquin.icap.columbia.edu/wp-content/uploads/2021/11/5th-CQUIN-Annual- |
|-----|--|
| 413 | Virtual-Meeting-Nov-21_Zambia-MoH-presentation_DrPLM.pdf |
| 414 | 16. Roscoe, C., Lockhart, C., de Klerk, M. et al. Evaluation of the uptake of tuberculosis |
| 415 | preventative therapy for people living with HIV in Namibia: a multiple methods |
| 416 | analysis. BMC Public Health20, 1838 (2020). https://doi.org/10.1186/s12889-020- |
| 417 | 09902-z |
| 418 | 17. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan |
| 419 | Africa: a systematic review. PLoS Med. 2011;8(7):e1001056. |
| 420 | 18. Babigumira JB, Castelnuovo B, Stergachis A, et al. Cost effectiveness of a pharmacy- |
| 421 | only refill program in a large urban HIV/AIDS clinic in Uganda. PloS one. |
| 422 | 2011;6(3):e18193. |
| 423 | 19. Selke HM, Kimaiyo S, Sidle JE, et al. Task-shifting of antiretroviral delivery from health |
| 424 | care workers to persons living with HIV/AIDS: clinical outcomes of a community-based |
| 425 | program in Kenya. Journal of acquired immune deficiency syndromes. 2010;55(4):483- |
| 426 | 490. |
| 427 | 20. Bemelmans M, Baert S, Goemaere E, et al. Community-supported models of care for |
| 428 | people on HIV treatment in sub-Saharan Africa. Tropical medicine & international health |
| 429 | : TM & IH. 2014;19(8):968-977. |
| 430 | 21. Boyd AT, Moore B, Shah M, et al . Implementing TB preventive treatment within |
| 431 | differentiated HIV service delivery models in global programs. Public Health Action. |
| 432 | 2020 Sep 21;10(3):104-110. doi: 10.5588/pha.20.0014. PMID: 33134124; PMCID: |
| 433 | PMC7577005. |
| | |

- 434 22. Kagujje et al. BMC Public Health (2019) 19:1329 <u>https://doi.org/10.1186/s12889-019-</u>
- 435 <u>7652-x</u>
- 436 23. https://www.zamra.co.zm/wp-content/uploads/2021/02/ZAMBIA-
- 437 PHARMACOVIGILANCE-Handbook-March-2020.pdf
- 438 *24.* Tram KH, Mwangwa F, Chamie G, et al. Predictors of isoniazid preventive therapy
- 439 completion among HIV-infected patients receiving differentiated and non-differentiated
- 440 HIV care in rural Uganda. *AIDS Care*. 2020;32(1):119-127.
- doi:10.1080/09540121.2019.1619661
- 442 25. Zambia COP20 POART PEPFAR Report
- 443 26. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and
- 444 Operational Research: Community-Based Adherence Clubs for the Management of Stable
- 445 Antiretroviral Therapy Patients in Cape Town, South Africa: A Cohort Study. J Acquir
- 446 Immune Defic Syndr. 2016 Jan 1;71(1):e16-23. doi: 10.1097/QAI.0000000000863.
- 447 PMID: 26473798.
- 448 27. Nachega JB, Adetokunboh O, Uthman OA, Knowlton AW, Altice FL, Schechter M,
- 449 Galárraga O, Geng E, Peltzer K, Chang LW, Van Cutsem G, Jaffar SS, Ford N, Mellins
- 450 CA, Remien RH, Mills EJ. Community-Based Interventions to Improve and Sustain
- 451 Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low-
- 452 and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. Curr
- 453 HIV/AIDS Rep. 2016 Oct;13(5):241-55. doi: 10.1007/s11904-016-0325-9. PMID:
- 454 27475643; PMCID: PMC5357578.

| 455 | 28. Hanrahan CKH, Dowdy D, et al. Patient preferences for provision of isoniazid preventive |
|-----|--|
| 456 | therapy among people living with HIV in South Africa; 47th Union World Lung Health |
| 457 | Conference; Liverpool, England. |
| 458 | 29. Adams LV, et al. Interventions to improve delivery of IPT: an overview of systematic |
| 459 | reviews. BMC infectious diseases. 2014;14:281 |
| 460 | 30. Sensalire, S., Karungi Karamagi Nkolo, E., Nabwire, J. et al. A prospective cohort study |
| 461 | of outcomes for isoniazid prevention therapy: a nested study from a national QI |
| 462 | collaborative in Uganda. AIDS Res Ther 17, 28 (2020). https://doi.org/10.1186/s12981- |
| 463 | <u>020-00285-0</u> |
| 464 | 31. World Health Organization. Global Tuberculosis Report 2019. World Health |
| 465 | Organization, Geneva; 2019, https://www.who.int/publications/i/item/9789241565714 |
| 466 | 32. Roy Monika,Bolton-Moore C, Sikazwe I Mukumbwa-Mwenechanya M et al. |
| 467 | Participation in adherence clubs and on-time drug pickup among HIV-infected adults in |
| 468 | Zambia: A matched-pair cluster randomized trial ,PLoS Medicine, volume 17,2020, |
| 469 | https://doi.org/10.1371/journal.pmed.1003116 |
| 470 | 33. Grimsrud A, Bygrave H, Doherty M, Ehrenkranz P, Ellman T, Ferris R, et al. |
| 471 | Reimagining HIV service delivery: the role of differentiated care from prevention to |
| 472 | suppression. J Int AIDS Soc. 2016; 19(1):21484. https://doi.org/10.7448/IAS.19.1.21484 |
| 473 | PMID: 27914186 |
| 474 | 34. Duncombe C, Rosenblum S, Hellmann N, Holmes C, Wilkinson L, Biot M, et al. |
| 475 | Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int |
| 476 | Health. 2015; 20(4):430-47. https://doi.org/10.1111/tmi.12460 PMID: 25583302 |

- 477 35. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects
- 478 of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort
- 479 study. Drug Healthc Patient Saf. 2014 Oct 20;6:145-9. doi: 10.2147/DHPS.S68837.
- 480 PMID: 25364275; PMCID: PMC4211866.)
- 481 36. Van der Watt JJ, Harrison TB, Benatar M, Heckmann JM. Polyneuropathy, anti-
- 482 tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic
- 483 review. Int J Tuberc Lung Dis. 2011;15(6):722–8.
- 484 37. Centre for Global Health Division; Division of Global HIV and TB; TB PREVENTIVE
- 485 TREATMENT: Sorting Myth from Fact:
- 486 https://static1.squarespace.com/static/5a29b53af9a61e9d04a1cb10/t/5e1c9e2bd9b49945
- 487 4924a2d4/1578933807928/02_TPT+Myth_Busters_20191024_clean.pdf
- 488 38. Ehrenkranz, Peter, Grimsrud, Anna, Holmes, Charles, Preko, Peter; Rabkin,
- 489 Miriam. Expanding the Vision for Differentiated Service Delivery: A Call for More
- 490 Inclusive and Truly Patient-Centered Care for People Living With HIV, JAIDS Journal
- 491 of Acquired Immune Deficiency Syndromes: February 1, 2021 Volume 86 Issue 2 p
- 492 147-152 doi: 10.1097/QAI.000000000254